Product image of Myoview (Tetrofosmin) supplied by GNH India

Myoview

Active Ingredient:
Tetrofosmin
Origin:
EU

Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed for myocardial perfusion imaging to assess regional blood flow and detect coronary artery disease in adult patients.

GNH India supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Ge Healthcare As

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myoview is used in cardiac diagnostic imaging to evaluate myocardial blood flow and identify ischemic regions.

  • Myocardial perfusion imaging: provides quantitative assessment of regional myocardial blood flow.
  • Coronary artery disease detection: helps visualize perfusion defects indicative of obstructive coronary lesions.
  • Ischemic heart disease evaluation: supports risk stratification and management decisions in patients with suspected ischemia.

How It Works

  • Tetrofosmin is labeled with technetium‑99m and, after intravenous injection, distributes proportionally to regional myocardial blood flow. The compound is taken up by viable myocardial cells, where its retention reflects perfusion. Single‑photon emission computed tomography (SPECT) then detects the gamma emissions, producing high‑resolution images of myocardial perfusion patterns.

Side Effects

Adverse reactions may occur following administration of Myoview.

Common Side Effects

  • Nausea: mild to moderate discomfort.
  • Flushing: transient warmth or redness.
  • Headache: mild to moderate intensity.
  • Dizziness: occasional light‑headedness.
  • Mild hypotension: temporary blood pressure drop.
  • Injection site pain: brief discomfort at the venipuncture site.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.
  • Severe hypotension: marked drop in blood pressure.
  • Cardiac arrhythmia: abnormal heart rhythm.
  • Myocardial infarction: rare occurrence of heart attack.
  • Severe allergic reaction: including bronchospasm.
  • Pulmonary edema: fluid accumulation in the lungs.

Precautions & Warnings

Prior to Myoview administration, clinicians should consider several safety measures.

  • Patient assessment: evaluate renal function and overall cardiovascular status.
  • Contraindications: avoid in patients with known hypersensitivity to tetrofosmin or technetium‑99m compounds.
  • Pregnancy: use only if the diagnostic benefit outweighs potential fetal risk.
  • Breastfeeding: discontinue breastfeeding or suspend the drug until cleared.
  • Drug interactions: review concurrent medications that may affect myocardial blood flow.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Myoview may interact with other agents that influence myocardial perfusion or radiopharmaceutical distribution.

Major Interactions (Avoid)

  • Amiodarone: may alter myocardial uptake of tetrofosmin.
  • Vasodilators (e.g., nitroglycerin): can increase redistribution and affect image interpretation.
  • Chemotherapeutic agents: may interfere with clearance and biodistribution.

Moderate Interactions (Monitor Closely)

  • Calcium channel blockers: may modestly modify perfusion patterns.
  • ACE inhibitors: potential effect on coronary flow.
  • Diuretics: possible influence on renal excretion of technetium‑99m.

Frequently Asked Questions

Myoview is a radiopharmaceutical used for myocardial perfusion imaging. It helps visualize blood flow to the heart muscle during SPECT scans, allowing clinicians to detect coronary artery disease, assess ischemic regions, and guide treatment decisions in adult patients.

Tetrofosmin, labeled with technetium‑99m, is injected intravenously and distributes in proportion to regional myocardial blood flow. Viable heart cells take up the compound, and its gamma emissions are captured by SPECT cameras, producing detailed images of perfusion patterns across the myocardium.

The prescribed dose of Myoview is determined by the treating physician or nuclear medicine specialist based on the specific imaging protocol, patient weight, and clinical indication. Dosing is individualized and should follow the prescribing information provided by the healthcare professional.

Safety data for Myoview in pregnancy and lactation are limited. It should only be used when the diagnostic benefit outweighs potential risks to the fetus. Breastfeeding mothers are generally advised to discontinue nursing or suspend the drug until cleared, in consultation with their physician.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the team will provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Myoview (technetium‑99m tetrofosmin) offers rapid myocardial uptake and high image quality, similar to technetium‑99m sestamibi. Compared with thallium‑201 agents, tetrofosmin provides lower radiation dose and better photon energy for SPECT, facilitating clearer images and shorter acquisition times.

Myoview must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Ensure the product remains within the recommended temperature range throughout transport and handling to maintain radiochemical stability.

Myoview is administered as an intravenous injection by a qualified healthcare professional. The solution is drawn from the vial and injected into a peripheral vein, typically followed by a brief waiting period before SPECT image acquisition begins.

Serious risks, though rare, include anaphylactic reactions, severe hypotension, cardiac arrhythmias, myocardial infarction, and pulmonary edema. Immediate medical attention is required if any of these events occur during or after the injection.

Myoview should not be administered to individuals with known hypersensitivity to tetrofosmin, technetium‑99m compounds, or any component of the formulation. It is also contraindicated in patients where the diagnostic benefit does not outweigh potential risks, such as certain pregnant or lactating women without appropriate justification.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrofosmin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT